DOCSLIB.ORG

Nanotechnology and Human Health Scientific Evidence and Risk

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Nanotechnology and human health: Scientific evidence and risk governance Report of the WHO expert meeting 10–11 December 2012, Bonn, Germany Nanotechnology and human health: Scientific evidence and risk governance Report of the WHO expert meeting 10–11 December 2012, Bonn, Germany ABSTRACT Nanotechnology, the science and application of objects smaller that 100 nanometres, is evolving rapidly in many fields. Besides the countless beneficial applications, including in health and medicine, concerns exist on adverse health consequences of unintended human exposure to nanomaterials. In the 2010 Parma Declaration on Environment and Health, ministers of health and of environment of the 53 Member States of the WHO Regional Office for Europe listed the health implications of nanotechnology and nanoparticles among the key environment and health challenges. The WHO Regional Office for Europe undertook a critical assessment of the current state of knowledge and the key evidence on the possible health implications of nanomaterials, with a view to identify options for risk assessment and policy formulation, and convened an expert meeting to address the issue. Current evidence is not conclusive. As complexity and uncertainty are large, risk assessment is challenging, and formulation of evidence-based policies and regulations elusive. Innovative models and frameworks for risk assessment and risk governance are being developed and applied to organize the available evidence on biological and health effects of nanomaterials in ways to inform policy. Keywords NANOPARTICLES — NANOTECHNOLOGY — PHARMACEUTICALS AND BIOLOGICALS — RISK MANAGEMENT — TOXICOLOGY Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe UN City, Marmorvej 51 DK-2100 Copenhagen Ø, Denmark Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office web site (http://www.euro.who.int/pubrequest). Citation advice: Nanotechnology and human health: Scientific evidence and risk governance. Report of the WHO expert meeting 10–11 December 2012, Bonn, Germany. Copenhagen, WHO Regional Office for Europe, 2013. © World Health Organization 2013 All rights reserved. The Regional Office for Europe of the World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The views expressed by authors, editors, or expert groups do not necessarily represent the decisions or the stated policy of the World Health Organization. Copy-editing: Elias Owen Design: Marta Pasqualato V Content Abbreviations VII Acknowledgements VIII 1. Introduction 1 1.1. Global nanomaterial uses and trends 1 2. Exposure assessment 2 2.1. Assessing direct and secondary exposures 2 2.2. Determination of exposure metrics 3 2.3. Exposure in children and other vulnerable subgroups 3 2.4. Exposure assessment and toxicological data generation 3 3. Nanotoxicology 4 3.1. General toxicological methods 4 3.2. Possible adverse health effects 4 3.3. Vulnerable subgroups 5 4. Risk assessment 5 4.1. Assessing risks of nanomaterials one by one 5 4.2. Options for evolution of risk assessment 6 4.3. Life-cycle perspective of nanoproducts 7 4.4. Detection, tracking and monitoring 7 5. Regulation and risk governance 7 5.1. Regulatory initiatives under way 7 5.2. Risk governance 8 5.3. Risk communication 10 5.4. Multistakeholder dialogue 10 5.5. Transboundary environmental, health and safety issues 10 VI Nanotechnology and human health: Scientific evidence and risk governance 6. Conclusion 11 References 11 Annex 1 15 NANO SUPPORT – Assessment of nanomaterials in REACH registration dossiers 17 Control/risk banding nano tools 18 European Chemicals Agency activities on nanomaterials 21 REACH implementation projects on nanomaterials: Outcomes and implementation 23 Nanomaterials in EU regulation 29 Pulmonary effects of exposure to nanoparticles 30 The IRGC Risk Governance Framework: Applications in food and cosmetics 33 Annex 2 35 Scope and Purpose 37 Programme 38 List of participants 40 Annex 3 43 Background Document 45 VII Abbreviations μg microgram μm micrometre ANSES French Agency for Food, Environmental and Occupational Health and Safety CB Control Banding CLP Classification, Labelling and Packaging of chemicals CNT carbon nanotube CoRAP Community Rolling Action Plan EC European Commission ECHA European Chemicals Agency EINECS European Chemical Substances Information System EU European Union GAARN Group Assessing Already Registered Nanomaterials GMO genetically modified organism IOM Institute of Occupational Medicine IRGC International Risk Governance Council ITS Integrated Testing Strategies IUCLID International Uniform Chemical Information Database MWCNT multiwalled carbon nanotube NIOSH National Institute for Occupational Safety and Health nm nanometre OC operational conditions OECD Organisation for Economic Co-operation and Development OEL occupational exposure limit REACH Registration, Evaluation, Authorisation and Restriction of Chemicals REL recommended exposure level RIP-oN REACH Implementation Project on Nanomaterials SAA serum amyloid A SDS safety data sheets SWCNTs single-walled carbon nanotubes TWA time-weighted average WHO World Health Organization WPMN OECD Working Party on Manufactured Nanomaterials VIII Nanotechnology and human health: Scientific evidence and risk governance Acknowledgements Preparatory work was based on results from the EU co-funded PAVEL Project (Grant Agreement 2006WHO01). The German Ministry of Environment, Natural Conservation and Nuclear Safety financially supported the meeting and the preparation of the report. The meeting was chaired by Professor Michael Depledge, University of Exeter Medical School, and the rapporteur was Dr Steffen F. Hansen, Technical University of Denmark. The report was edited by Steffen F. Hansen, Charles V. Howard, Marco Martuzzi and Michael Depledge. Participants in the expert meeting reviewed the text and provided comments. Report of the WHO expert meeting 10–11 December 2012, Bonn, Germany Meeting report 1 1. Introduction Nanomaterials and products based on nanotechnological applications are being commercialized and used at an increasing pace. In the Parma Declaration on Environment and Health,1 the health implications of nanotechnology and nanoparticles are listed among the key environment and health challenges that ministers are committed to act on. Along with a call for increased research on the use of nanoparticles in products and nanomaterials, the ministers pledged to develop and use improved health risk and benefit assessment methods. Research into the environmental, health and safety aspects of nanomaterials is extensive and growing rapidly. The World Health Organization (WHO) Regional Office for Europe has been reviewing recent and current research, with a view to clarifying the connections between nanotechnology and health. Findings from this exercise suggest that a rigorous risk assessment is not feasible and that a pragmatic model of “risk governance” seems desirable. In order to explore how the Regional Office can contribute to progressing risk governance of nanotechnologies, a two-day workshop was held in December 2012. Participants with a wide range of expertise were invited to present their work, with the purpose of providing input to WHO. A background document on nanotechnology and health (not representing a comprehensive or systematic overview of the issue) was used as the basis for this meeting and is included in this report. Abstracts of the presentations made by participants are included in the annex. The workshop’s discussion focused on four key areas (i) exposure assessment of nanomaterials, (ii) nanotoxicology, (iii) risk assessment, and (iv) regulation and risk governance. 1.1. Global nanomaterial uses and trends Nanomaterials are making their way into all aspects of our lives; these materials are being increasingly used in pharmaceutical and medical applications, cosmetics and personal products, energy storage and efficiency, water treatment and air filtration, environmental remediation, chemical and biological sensors, military defence and explosives (Chaudhry, 2012), and in countless consumer products and materials. For instance, in the area of food, nanomaterials
Recommended publications
  • Understanding Lead Uptake and Effects Across Species Lines: a Conservation Medicine Based Approach

    Understanding Lead Uptake and Effects Across Species Lines: a Conservation Medicine Based Approach

    UNDERSTANDING LEAD UPTAKE AND EFFECTS ACROSS SPECIES LINES: A CONSERVATION MEDICINE BASED APPROACH MARK A. POKRAS AND MICHELLE R. KNEELAND Center for Conservation Medicine, Tufts University Cummings School of Veterinary Medicine, 200 Westboro Rd., North Grafton, MA 01536, USA. E-mail: [email protected] ABSTRACT.—Conservation medicine examines the linkages among the health of people, animals and the environment. Few issues illustrate this approach better than an examination of lead (Pb) toxicity. We briefly review the current state of knowledge on the toxicity of lead and its effects on wildlife, humans, and domestic animals. Lead is cheap and there is a long tradition of its use. But the toxic effects of Pb have also been recognized for centuries. As a result, western societies have greatly reduced many traditional uses of Pb, including many paints, gasoline and solders because of threats to the health of humans and the environment. Legisla- tion in several countries has eliminated the use of lead shot for hunting waterfowl. Despite these advances, a great many Pb products continue to be readily available. Conservationists recognize that hunting, angling and shooting sports deposit thousands of tons of Pb into the environment each year. Because of our concerns for human health and over 100 years of focused research, we know the most about lead poisoning in people. Even today, our knowledge of the long-term sublethal effects of Pb on human health continues to grow dramatically. Our knowledge about lead poisoning in domestic animals is signifi- cantly less. For wild animals, our understanding of lead poisoning is roughly where our knowledge about humans was in the mid-1800s when Tanquerel Des Planches made his famous medical observations (Tan- querel Des Planches 1850).
  • WO 2016/110768 Al 14 July 2016 (14.07.2016) W P O PCT

    WO 2016/110768 Al 14 July 2016 (14.07.2016) W P O PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/110768 Al 14 July 2016 (14.07.2016) W P O PCT (51) International Patent Classification: Rue de la Blancherie 11, 1022 Chavannes-pres-Renens A61K 35/74 (2015.01) A61P 25/28 (2006.01) (CH). HANNA, Walid; Avenue des Bains 40, 1007 Lausanne (CH). FAK, Frida; Qvantenborgsvagen 4B, 227 (21) International Application Number: 38 Lund (SE). MARUNGRUANG, Nittaya; Ostra Varvs- PCT/IB2015/059945 gatan 20A, 2 11 75 Malmo (SE). (22) International Filing Date: (74) Agent: ROLAND, Andre; c/o ANDRE ROLAND S.A., 23 December 2015 (23. 12.2015) P.O. Box 5107, 1002 Lausanne (CH). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/IB20 15/050 127 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 7 January 2015 (07.01 .2015) IB HN, HR, HU, ID, IL, ΓΝ , IR, IS, JP, KE, KG, KN, KP, KR, PCT/IB2015/053957 27 May 2015 (27.05.2015) IB KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (71) Applicant: ECOLE POLYTECHNIQUE FEDERALE MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, DE LAUSANNE (EPFL) [CH/CH]; EPFL-TTO, EPFL PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, Innovation Park J, 1015 Lausanne (CH).
  • Nanoscience and Nanotechnologies: Opportunities and Uncertainties

    Nanoscience and Nanotechnologies: Opportunities and Uncertainties

    ISBN 0 85403 604 0 © The Royal Society 2004 Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the UK Copyright, Designs and Patents Act (1998), no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior permission in writing of the publisher, or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of licenses issued by the appropriate reproduction rights organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to: Science Policy Section The Royal Society 6–9 Carlton House Terrace London SW1Y 5AG email [email protected] Typeset in Frutiger by the Royal Society Proof reading and production management by the Clyvedon Press, Cardiff, UK Printed by Latimer Trend Ltd, Plymouth, UK ii | July 2004 | Nanoscience and nanotechnologies The Royal Society & The Royal Academy of Engineering Nanoscience and nanotechnologies: opportunities and uncertainties Contents page Summary vii 1 Introduction 1 1.1 Hopes and concerns about nanoscience and nanotechnologies 1 1.2 Terms of reference and conduct of the study 2 1.3 Report overview 2 1.4 Next steps 3 2 What are nanoscience and nanotechnologies? 5 3 Science and applications 7 3.1 Introduction 7 3.2 Nanomaterials 7 3.2.1 Introduction to nanomaterials 7 3.2.2 Nanoscience in this area 8 3.2.3 Applications 10 3.3 Nanometrology
  • Green Parties and Elections to the European Parliament, 1979–2019 Green Par Elections

    Green Parties and Elections to the European Parliament, 1979–2019 Green Par Elections

    Chapter 1 Green Parties and Elections, 1979–2019 Green parties and elections to the European Parliament, 1979–2019 Wolfgang Rüdig Introduction The history of green parties in Europe is closely intertwined with the history of elections to the European Parliament. When the first direct elections to the European Parliament took place in June 1979, the development of green parties in Europe was still in its infancy. Only in Belgium and the UK had green parties been formed that took part in these elections; but ecological lists, which were the pre- decessors of green parties, competed in other countries. Despite not winning representation, the German Greens were particularly influ- enced by the 1979 European elections. Five years later, most partic- ipating countries had seen the formation of national green parties, and the first Green MEPs from Belgium and Germany were elected. Green parties have been represented continuously in the European Parliament since 1984. Subsequent years saw Greens from many other countries joining their Belgian and German colleagues in the Euro- pean Parliament. European elections continued to be important for party formation in new EU member countries. In the 1980s it was the South European countries (Greece, Portugal and Spain), following 4 GREENS FOR A BETTER EUROPE their successful transition to democracies, that became members. Green parties did not have a strong role in their national party systems, and European elections became an important focus for party develop- ment. In the 1990s it was the turn of Austria, Finland and Sweden to join; green parties were already well established in all three nations and provided ongoing support for Greens in the European Parliament.
  • The Nanotoxicology of a Newly Developed Zero-Valent Iron

    The Nanotoxicology of a Newly Developed Zero-Valent Iron

    The nanotoxicology of a newly developed zero-valent iron nanomaterial for groundwater remediation and its remediation efficiency assessment combined with in vitro bioassays for detection of dioxin-like environmental pollutants Von der Fakultät für Mathematik, Informatik und Naturwissenschaften der RWTH Aachen University zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigte Dissertation vorgelegt von Diplom-Biologe Andreas Herbert Schiwy aus Tarnowitz (Polen) Berichter: Universitätsprofessor Dr. rer. nat. Henner Hollert Universitätsprofessor Dr. rer. nat. Andreas Schäffer Tag der mündlichen Prüfung 28. Juli 2016 Diese Dissertation ist auf den Internetseiten der Universitätsbibliothek online verfügbar. To my wife and my children Summary Summary The assessment of chemicals and new compounds is an important task of ecotoxicology. In this thesis a newly developed zero-valent iron material for nanoremediation of groundwater contaminations was investigated and in vitro bioassays for high throughput screening were developed. These two elements of the thesis were combined to assess the remediation efficiency of the nanomaterial on the groundwater contaminant acridine. The developed in vitro bioassays were evaluated for quantification of the remediation efficiency. Within the NAPASAN project developed iron based nanomaterial showed in a model field application its nanoremediation capabilities to reduce organic contaminants in a cost effective way. The ecotoxicological evaluation of the nanomaterial in its reduced and oxidized form was conducted with various ecotoxicological test systems. The effects of the reduced nanomaterial with field site resident dechlorinating microorganisms like Dehalococcoides sp., Desulfitobacterium sp., Desulfomonile tiedjei, Dehalobacter sp., Desulfuromonas sp. have been investigated in batch und column experiments. A short-term toxicity of the reduced nanomaterial was shown.
  • Environmental Risk Assessment of Chemicals

    Environmental Risk Assessment of Chemicals

    Society of Environmental Toxicology and Chemistry Technical Issue Paper Environmental Risk Assessment of Chemicals Environmental Risk exposure to a chemical for organisms, such as animals, plants, or microbes, in the environment, which could be Assessment of Chemicals water, soil, or air. Effects can be assessed at different levels of biological organization, which is to say in Environmental risk assessment determines the single cells, individuals, populations, ecosystems, or nature and likelihood of harmful effects occurring landscapes. to organisms such as humans, animals, plants, or microbes, due to their exposure to stressors. A stressor can be a chemical (such as road salt runoff to a lake), Applications of Environmental exotic species (such as a foreign plant), or a change Risk Assessment of Chemicals in physical conditions (such as dredging a channel). Here, we focus on risk assessment of chemicals. The Environmental risk assessments of chemicals can be chemicals can be something that is found in nature, used at many scales. They can take place at the small- such as copper, or something created by humans, such scale site level (such as a release at a manufacturing as pharmaceuticals. Depending on whether humans plant), at the field-scale level (for example, spraying or other organisms or ecosystems are exposed, a plant protection products or pesticides on crops), risk assessment is called either a “human health” or at a regional level (such as a river catchment or an “ecological” risk assessment. Here, the term or bay). Policy makers, including government “environmental risk assessment” is used to include both. agencies, and industries use risk assessments to support environmental management decisions.
  • Nanotechnology and Health Risks

    Nanotechnology and Health Risks

    NANOTECHNOLOGY AND HEALTH RISKS Nanotechnology is being hailed as the “next industrial revolution”. Nanomaterials are now found in hundreds of products, from cosmetics to clothing to food products. Inevitably, these nanomaterials will enter our bodies as we handle nanomaterials in the workplace, eat nano-foods, wear nano-clothes and nano- cosmetics, use nano-appliances and dispose of nano waste into the environment. Early scientific studies demonstrate the potential for materials that are benign in bulk form to become harmful at the nanoscale. There is an urgent need for regulations to protect workers, the public and the environment from nanotoxicity’s risks, for greater understanding of the short and long-term implications of nanotechnology for people’s health and the environment, for consideration of nanotechnology’s broader social implications and for public involvement in decision making regarding nanotechnology’s introduction. What is “nanotechnology” and how is it used? “Nanotechnology” refers to the design, production and application of structures, devices or systems at the incredibly small scale of atoms and molecules – the “nanoscale”. “Nanoscience” is the study of phenomena and the manipulation of materials at this scale, generally understood to be 100 nanometres (nm) or less1. To put 100nm in context, a single strand of DNA measures 2.5nm across, red blood cells measure about 7,000nm and a human hair is 80,000nm wide. Most observers do not make a distinction between nanotechnology and nanoscience and use the term nanotechnology to encompass production and use of nanoscale materials (“nanomaterials”). Nanomaterials are “first generation” products of nanotechnology and FACT SHEET have already entered wide-scale commercial use.
  • A Toxicology Curriculum for Communities

    A Toxicology Curriculum for Communities

    A Toxicology Curriculum For Communities 43 Module One Introduction to Toxicology 44 Objectives Upon completion of this module, the learner will be able to: Define toxicology and commonly associated terms Differentiate the sub-disciplines of toxicology Describe the classifications of toxic agents Describe the field of toxicology Understand the roles of various agencies Identify potential sources for additional information 45 What is Toxicology? 46 Toxicology Involves all aspects of the adverse effects of chemicals on living systems. 47 General Toxicology Questions 48 What are Harmful or Adverse Effects? Those effects which are damaging to either the survival or normal function of the individual 49 What is Toxicity? The term “toxicity”is used to describe the nature of adverse effects produced and the conditions necessary for their production. Before toxicity can develop, a substance must come into contact with a body surface such as skin, eye or mucosa of the alimentary or respiratory tract. 50 What is Toxic? This term relates to poisonous or deadly effects on the body 51 What is a Toxicant? The term “toxicant” refers to toxic substances that are produced by or are a by- product of human-made activities. 52 What is a Toxin? The term “toxin” refers to toxic substances that are produced naturally. 53 What is a Toxic Symptom? What is a Toxic Effect ? A toxic symptom is any feeling or sign indicating the presence of a poison in the system. Toxic effects refers to the health effects that occur due to exposure to a toxic substance. 54 What is Selective Toxicity? This means that a chemical will produce injury to one kind of living matter without harming another form of life, even though the two may exist close together.
  • Nanotoxicology: Toxicological and Biological Activities of Nanomaterials - Yuliang Zhao, Bing Wang, Weiyue Feng, Chunli Bai

    Nanotoxicology: Toxicological and Biological Activities of Nanomaterials - Yuliang Zhao, Bing Wang, Weiyue Feng, Chunli Bai

    NANOSCIENCE AND NANOTECHNOLOGIES - Nanotoxicology: Toxicological and Biological Activities of Nanomaterials - Yuliang Zhao, Bing Wang, Weiyue Feng, Chunli Bai NANOTOXICOLOGY: TOXICOLOGICAL AND BIOLOGICAL ACTIVITIES OF NANOMATERIALS Yuliang Zhao, CAS Key Lab for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, The Chinese Academy of Sciences, Beijing 100049, & National Center for Nanoscience and Technology of China, Beijing 100190, China Bing Wang, CAS Key Lab for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, The Chinese Academy of Sciences, Beijing 100049 Weiyue Feng, CAS Key Lab for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, The Chinese Academy of Sciences, Beijing 100049 Chunli Bai National Center for Nanoscience and Technology of China, Beijing 100190, China The Chinese Academy of Sciences, Beijing 100864, China Keywords: Nanotoxicology, Nanosafety, Nanomaterials, Nanoparticles, Contents 1. Introduction 2. Target organ toxicity of nanoparticles 2.1. Respiratory System 2.1.1. Deposition of Nanoparticles in the Respiratory Tract 2.1.2. Clearance of Nanoparticles in the Respiratory Tract 2.1.3. Nanotoxic Response of Respiratory System 2.2. Gastrointestinal System 2.3. Cardiovascular System 2.4. Central Nervous System 2.5. Skin 3. Absorption,UNESCO distribution, metabolism and excretion– EOLSS of nanoparticles (ADME) 3.1. ADME of Nanoparticle Following Inhalation Exposure 3.1.1. Absorption and Retention of Nanoparticles Following Respiratory Tract Exposure 3.1.2. Translocation and Distribution of Nanoparticles Following Respiratory Tract Exposure SAMPLE CHAPTERS 3.1.3. Metabolism and Excretion of Nanoparticles in the Lung 3.2. ADME of Nanoparticle via Gastrointestinal Tract 3.3. ADME of Nanoparticles via Skin 4.
  • Introduction to Environmental Toxicology

    Introduction to Environmental Toxicology

    Introduction to Toxicology WATER BIOLOGY PHC 6937; Section 4858 Andrew S. Kane, Ph.D. Department of Environmental & Global Health College of Public Health & Health Professions [email protected] ? “The problem with toxicology is not the practicing toxicologists, but chemists who can detect, precisely, toxicologically insignificant amounts of chemicals” Rene Truhaut, University of Paris (1909-1994) Toxicology………… • Is the study of the harmful effects of chemicals and physical agents on living organisms • Examines adverse effects ranging from acute to long-term chronic • Is used to assess the probability of hazards caused by adverse effects • Is used to predict effects on individuals, populations and ecosystems 1 An interdisciplinary field… Clinical Toxicology: Diagnosis and treatment of poisoning; evaluation of methods of detection and intoxication, mechanism of action in humans (human tox, pharmaceutical tox) and animals (veterinary tox). Integrates toxicology, clinical medicine, clinical biochemistry/pharmacology. Environmental Toxicology: Integrates toxicology with sub- disciplines such as ecology, wildlife and aquatic biology, environmental chemistry. Occupational Toxicology: Combines occupational medicine and occupational hygiene. An interdisciplinary field… Descriptive Toxicology: The science of toxicity testing to provide information for safety evaluation and regulatory requirements. Mechanistic Toxicology: Identification and understanding cellular, biochemical & molecular basis by which chemicals exert toxic effects. Regulatory Toxicology:
  • Nanotoxicology Program Jenny R

    Nanotoxicology Program Jenny R

    Nanotoxicology Program Jenny R. Roberts, Ph.D. HELD/ACIB NTRC Toxicology and Internal Dose Critical Area Coordinator National Institute for Occupational Safety and Health Morgantown, WV Definitions • Nanoparticle: – A particle having one dimension less than 100 nm. Carbon Nanotube (1 nanometer) x 100,000 = Strand of Hair (100 microns) • Engineered Nanoparticle: – Created for a purpose with tightly controlled size, shape, surface features and chemistry. • Incidental Nanoparticle: – Created as an inadvertent side product of a process. Growth of Nanotoxicology as a Field of Study Scopus: Nanoparticles and Toxicity 3000 2500 1990's Emergence of Nanotech Companies 2000 2004 1st NTRC Science Meeting 1500 1980's Discovery of Early 1990's 2000 Nanocrystals Carbon 1000 National and Fullerenes Nanotubes Publication Number Publication Nanotechnology Innitiative 500 0 1980 1985 1990 1995 2000 2005 2010 2015 Year Timeline and Images: www.nano.gov Nanotechnology Research Center (NTRC) NTRC: 10 Critical Areas NIOSH Program Toxicology & Internal Dose Measurement Recommendations & Guidance Methods Informatics & Exposure Applications Assessment NTRC Global Epidemiology & Collaborations Surveillance Risk Fire & Explosion Assessment Safety Controls & PPE 2016 Nanotoxicology Projects: 11 HELD, 13 NTRC > 40 Extramural Collaborations – Academia, Government, Industrial • Strategic Plan Goals Pertaining to Toxicology 1. Increase understanding of new hazards and related health risks to nanomaterial workers. Conduct research to contribute to the understanding of the toxicology and internal dose of emerging ENMs. Determine whether nanomaterial toxicity can be categorized on the basis of physicochemical properties and mode of action. 2. Expand understanding of the initial hazard findings of engineered nanomaterials. Determine whether human biomarkers of nanomaterial exposure and/or response can be identified.
  • Swans on a One Way Ticket

    Swans on a One Way Ticket

    4~lSlb • lr -fa NEWSLETTER OF THE MALTA ORNITHOLOGICAL SOCIETY ISSUE 10 FEBRUARY 93 Swans on a one way ticket Yes it has happened again! Some mindless. selfish and self proclaimed sportsmen have managed to eradicate a number of mute swans in less than two days, for what seemed to the swans as a temporary stop-over on our Islands. On Sunday. 10 January. a flock of around 24 graceful white mute swans were noticed in the vicinity of Ghadira Bay. On Monday morning. Charles Gauci. the warden at the Ghadira Nature Reserve called the MOS office to inform that a swan was resting in the Reserve. The MOS Director Paul Portelli was already becoming worried because since that evening there would be almost a full moon. this could prove to be of a disadvantage to the swan. The Director made all the necessary arrangements with the television crew of P.B.S.Ltd. to go and film this unusual visitor for the eight o'clock news. Imagine the sight of this and maybe other swans placidly enjoying our mild winter weather. One must remember that the last recorded sighting of mute swans in Malta was in 1985. But, how foolish we had been. We had underestimated the odds. At around 11.00am Charles Gauci informed us that the swan had left the Reserve. Once it left the protection of the Reserve it needed all the luck it could get. By 11.30 am we received a phone call informing us that some hunters were coming ashore at Xemxija with a dead swan as their victim.